Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramantamig plus daratumumab versus investigator's choice for newly diagnosed multiple myeloma
ISRCTN15262649Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised trial of ramantamig in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Progression-free survival and 12-month MRD-negative complete response rate. Started Sep 2026; status: recruiting.
02
Drugs
ramantamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ISRCTN15262649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15262649.